Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1994 1
1995 1
1996 1
1998 3
1999 3
2000 2
2003 1
2004 3
2006 2
2009 4
2010 8
2011 6
2012 7
2013 7
2014 13
2015 23
2016 24
2017 22
2018 16
2019 13
2020 11
2021 7
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27919501

160 results

Results by year

Filters applied: . Clear all
Page 1
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC. Plavina T, et al. Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15. Neurology. 2017. PMID: 28916537 Free PMC article. Clinical Trial.
Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F. Millonig A, et al. J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23. J Neuroimmunol. 2010. PMID: 20739072
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
Auer M, Bauer A, Oftring A, Rudzki D, Hegen H, Bsteh G, Di Pauli F, Berek K, Zinganell A, Berger T, Reindl M, Deisenhammer F. Auer M, et al. CNS Drugs. 2022 Oct;36(10):1121-1131. doi: 10.1007/s40263-022-00953-x. Epub 2022 Sep 29. CNS Drugs. 2022. PMID: 36173556
160 results